BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions Inc. (BLFS) reports that Glazer Capital, LLC and its managing member, Paul J. Glazer, each beneficially owned 4,084,488 common shares, or 8.4%, as of September 30, 2026. They reported shared voting and dispositive power over all of those shares and no sole voting or dispositive power.
Glazer Capital Enhanced Master Fund, Ltd., a fund managed by Glazer Capital, has the right to receive or direct the receipt of proceeds from sales of more than 5% of BLFS’s outstanding common shares. The reporting persons state that the disclosure is not an admission that either is a beneficial owner for purposes of Section 13.
BioLife Solutions, Inc. (BLFS) is the issuer in an amended Schedule 13G that lists 1,094,026 common shares as beneficially owned by T. Rowe Price Investment Management, Inc., equal to 2.2% of the class. The table reports sole voting and dispositive power over all 1,094,026 shares and no shared power. T. Rowe Price Investment Management expressly denies being the beneficial owner of the securities.
BioLife Solutions Inc. was the subject of BlackRock, Inc.’s amended beneficial-ownership report, which lists 6,577,306 common shares, or 13.4% of the class, as beneficially owned as of September 30, 2026. BlackRock reported sole voting power over 6,461,043 shares and sole dispositive power over 6,577,306 shares; shared voting and dispositive power were both zero.
BlackRock says the reported securities reflect holdings of certain business units and exclude securities attributed to business units whose ownership is disaggregated. The report identifies iShares Core S&P Small-Cap ETF as having an interest in more than 5% of BioLife Solutions’ outstanding common stock.
BioLife Solutions Inc. Chief Financial Officer Troy Wichterman reported acquiring 76,204 and 62,300 shares under restricted-stock awards on October 6, 2026. The awards vested immediately before the merger, at approximately 200% of the number of shares granted, based on separate performance periods. He also reported 95,933 shares withheld for tax obligations at $38.61 per share and the disposition of 256,000 shares in the merger. At the merger's effective time, each outstanding BioLife common share converted into the right to receive $11.25 in cash and 0.1442 Repligen common shares, subject to the merger agreement.
BioLife Solutions Inc. (BLFS) director Joydeep Goswami reported a direct disposition to the issuer of 53,156 common shares on October 6, 2026, in connection with the consummation of its merger with Repligen Corporation. His reported direct holdings after the transaction were 0 shares.
BioLife Solutions director Rachel Ellingson disposed of 57,995 common shares on October 6, 2026, in connection with the consummation of the merger involving Repligen. Each outstanding BioLife share converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the merger agreement. Ellingson reported zero shares held directly after the transaction.
BioLife Solutions (BLFS) reports that director Amy DuRoss disposed of 26,857 common shares in connection with the merger completed October 6, 2026; her reported direct holdings after the transaction were 0 shares. Under the merger terms, each outstanding share of BioLife Solutions common stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, subject to the Merger Agreement.